THAY ĐỔI NỒNG ĐỘ NT-PROBNP Ở BỆNH NHÂN SUY TIM

Abstract

Background: Heart failure is a common condition and results in high mortality in adults. NT-proBNP is used in diagnosing heart failure, but affected by various factors. The study aimed to investigate the changes in NT-proBNP levels in heart failure patients. Methods: A cross-sectional study on heart failure patients classified as NYHA class II admitted to the University of Medicine Center from May 2020 to May 2022. Results: 276 patients were recruited, including 129 men and 147 women. Mean age was 68. The median concentration of NT-proBNP in overweight and obesity heart failure patients and non obesity heart failure patients respectively 4933 (2112-11720) (pg/ml) and 3177 (1409-5927) (pg/ml) (p<0,001). The median concentration of NTproBNP by gender in the overweight and obese group in men was 2547 (1276-4574)(pg/ml) lower than the non-obese group in men by 3427 (1796-9892) (pg/ml) (p= 0.029). The median concentration of NT-proBNP according to overweight and obese women was 4039 (1414-8192) (pg/ml) and non-obese women was 4498 (2672-16191)(pg/ml) (p<0.028). This difference was statistically significant in both two genders. A statistically significant differences were also found in the concentration of NT-proBNP within the overweight and obese groups between men and women with (p=0.024). The concentration of NT-proBNP by age in the overweight and obese group at the age of 50 - 75 was 3151 (1575-6812) (pg/ml) and ≥ 75 was 3156 (1074-4975) (pg/ml) lower. the non-obese group at the age of 50 - 75 was 4988 (2066-10383) and ≥ 75 was 4343 (2435-16488) this difference was statistically significant with p<0.05. Conclusion: Plasma NT-proBNP concentrations in overweight and obese heart failure patients were lower than in non-obese heart failure patients according to gender and age groups. This is meaningful in adjusting the diagnosis and assessment of the patient's heart failure to agree with the patient's overweight and obesity status.